Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↓Deteriorating
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Jun 18, 2026
Medtronic plc. (MDT) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $94.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers of components, raw materials and services; Analyst target reached - limited upside remaining.
Medtronic, headquartered in Galway, Ireland, develops and sells device-based medical therapies in more than 150 countries across three segments: Cardiovascular, Neuroscience and Medical Surgical. Products include pacemakers, heart valves, ablation catheters, spinal cord... Read more
Hold if already holding. Not a fresh buy at $94.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers of components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 19d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
MiniMed's initial public offering on March 9, 2026 removed the Diabetes Operating Unit as a reportable segment in the fourth quarter of Medtronic's fiscal 2026, leaving three segments: the Cardiovascular, Neuroscience and Medical Surgical Portfolios. Founded in 1949 and headquartered in Galway, Ireland, Medtronic serves healthcare systems, physicians and patients in more than 150 countries and has over 95,000 full-time employees, 43% of them in the U.S. or Puerto Rico. Named products include the Micra leadless pacemaker, Evolut transcatheter aortic valves, Affera Sphere-360 pulsed field ablation catheters and the Hugo robotic-assisted surgery system.
The company sells implantable and surgical devices for specialists such as electrophysiologists, spine surgeons, neurosurgeons and general surgeons, with the Medical Surgical Portfolio used mainly by healthcare systems, physicians' offices and ambulatory surgical centers. Cardiovascular spans cardiac rhythm and heart failure, structural heart and aortic, and coronary and peripheral vascular divisions; Neuroscience covers cranial and spinal technologies, specialty therapies such as neurovascular and pelvic health, and neuromodulation including the Inceptiv spinal cord stimulation system; Medical Surgical covers surgical and endoscopy and acute care and monitoring. Reimbursement approval from healthcare insurance providers is listed among the factors that shape competitiveness. The filing says competition ranges from large multi-line companies to small niche manufacturers, and also names pharmaceutical alternatives, including GLP-1 drugs, without naming individual device rivals. Manufacturing occurs at numerous facilities worldwide using components from many suppliers, with certain components, raw materials and services obtained from sole suppliers.
Show full overview
Pricing and regulatory exposure are most specific outside the United States. Government pricing mechanisms such as volume-based procurement programs in China may require significant price concessions and, in some markets, retrospective payment adjustments or clawbacks that could force refunds of amounts already received. The EU Medical Device Regulation adds pre-market and post-market requirements, with implementation extended to the end of 2027 for high-risk devices and the end of 2028 for medium- and low-risk devices. FDA inspections of the company or its suppliers have led to Form 483 observations, warning letters and consent decrees, and enforcement against a third-party sterilizer could limit supply of affected products. Several key products depend on a particular manufacturing or sterilization facility with constrained capacity.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-10-29T11:48:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers of components, raw materials and services10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers'
- MEDIUMSuppliersterilization facilities10-K Item 1A: 'several of our key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $94.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers of components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Maintain position. Not compelling to add more. Analyst target $94.15 reached (−0.7%), stop $89.92 (−5.4%), A.R:R -0.1:1. Score 6.2/10, moderate confidence.
Analyst target $94.15 reached (−0.7% from $94.78); no take-profit level is published. Analyst target $94.15 reached (−0.7%), stop $89.92 (−5.4%), A.R:R -0.1:1. Stop-loss: $89.92.
Concentration risk — Supplier: sole suppliers of components, raw materials and services; Analyst target reached - limited upside remaining.
Medtronic plc. trades at a P/E of 23.3 (forward 14.8). TrendMatrix value score: 5.7/10. Verdict: Hold.
33 analysts cover MDT with a consensus score of 3.9/5. Average price target: $105.
What does Medtronic plc. do?Medtronic, headquartered in Galway, Ireland, develops and sells device-based medical therapies in more than 150...
Medtronic, headquartered in Galway, Ireland, develops and sells device-based medical therapies in more than 150 countries across three segments: Cardiovascular, Neuroscience and Medical Surgical. Products include pacemakers, heart valves, ablation catheters, spinal cord stimulators, surgical stapling and the Hugo robotic surgery system. Customers are healthcare systems, physicians and ambulatory surgical centers; the Diabetes business was separated through the March 2026 MiniMed IPO.